Quantcast

Viela Bio begins clinical trials months after $250M spinoff

One of Maryland’s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in financing and a promise of creating 100 jobs within five years. Monday’s announcement is a first ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

*